Case Based Peer Perspectives

Sagar Lonial, MD, FACP, presents a case of a 72-year-old man with heavily pretreated relapsed/refractory multiple myeloma and discusses treatment options for patients with this diagnosis who have failed multiple prior lines of therapy.

Shannon Westin, MD, analyzes the diagnosis and treatment of a 68-year-old woman with recurrent ovarian cancer.

Recommendations for using ruxolitinib to treat a 53-year-old patient with acute graft-versus-host disease whose disease progresses following previous treatment with steroid therapy.

Hematology/oncology expert, John P. Leonard, MD, describes the rationale for treating an elderly patient with relapsed/refractory follicular lymphoma with a PI3K inhibitor in the third-line setting.

Yi-Bin Chen, MD, reviews the case of a 50-year-old woman with steroid-refractory acute graft versus host disease (aGvHD) following allogeneic transplant and provides a discussion on treatment considerations for patients with aGvHD.

Nicholas Vogelzang, MD, FASCO, FACP, comments on managing an elderly patient with hormone-sensitive prostate cancer with apalutamide and ADT based on data demonstrated by the phase 3 TITAN trial.

Kartik Konduri, MD, reviews the case of a 68-year-old woman with small-cell lung cancer.

Sagar Lonial, MD, FACP, presents a case of a 78-year-old man with multiple myeloma and discusses the many facets of treatment for multiple myeloma in the elderly population.

Brian Hill, MD, reviews the case of a 73-year-old man with mantle cell lymphoma and discusses the latest data and treatment approaches.

Daniel Catenacci, MD, reviews the case of a 71-year-old man with gastric cancer.

Saad Usmani, MD, presents a case of a 75-year-old woman with multiple myeloma.

Saad Usmani, MD, presents a case of a 75-year-old woman with multiple myeloma.

Ticiana Leal, MD, presents a case of a 61-year-old man with small cell lung cancer.

Recommendations for using AR-targeted therapy as an approach when managing patients with metastatic castrate-sensitive prostate cancer.

Bassel El-Rayes, MD, reviews the case of a 66-year old man with gastric carcinoma and discusses the disease from diagnosis to unmet needs.

John M. Burke, MD, of Rocky Mountain Cancer Centers, explains the rationale behind treating an elderly woman with relapsed diffuse large B-cell lymphoma with tafasitamab and lenalidomide after R-CHOP chemotherapy.

Gilles Salles, MD, reviews the case of a 74-year-old man with diffuse large B-cell lymphoma.

Robert Alter, MD, of John Theurer Cancer Center, describes the rationale for treating a 58-year-old male with advanced renal cell carcinoma with the combination of lenvatinib and everolimus following progression on first-line therapy.

A key opinion leader reviews the case of a 71-year-old woman with NTRK gene fusion thyroid cancer and considers novel therapies available for the management of her disease.

Neeraj Agarwal, MD, reviews the case of a 73-year-old man with unresectable, locally advanced urothelial carcinoma and discusses latest data and treatment approaches.

Dr Robert Dreicer reviews a case of advanced urothelial cancer and explains the patient’s eligibility for platinum-based chemotherapy followed by maintenance therapy with a checkpoint inhibitor.

Lyudmila Bazhenova, MD, presents the case of a 58-year-old woman with ALK+ non–small cell lung cancer.

Javier Munoz, MD, MS, FACP, of the Mayo Clinic, considers the appropriateness for CAR T-cell therapy for a 66-year-old woman with relapsed/refractory mantle cell lymphoma.

A discussion on the management of a 64-year-old man with differentiated thyroid cancer, with special consider of the phase 3 SELECT trial regimen.

Medstar Georgetown University Hospital’s Dr Stephen Liu shares impressions on the way a 57-year-old man with ALK-positive metastatic non–small cell lung cancer was managed, highlighting the rationale for using a second-generation ALK inhibitor as treatment.

Lori Wirth, MD, provides insight on the case of a 67-year-old woman with differentiated thyroid cancer and examines the management of radioiodine-refractory disease.

An expert oncologist presents the case of a 69-year-old woman with advanced renal cell carcinoma, and considers available treatment options for patients with a similar disease setting.

Jeff Sharman, MD, reviews a case of a 79-year-old man with relapsed chronic lymphocytic leukemia.

Neeta Somaiah, MD, reviews the case of a 68-year-old man with gastrointestinal stromal tumor.

Ramez N. Eskander, MD, explains the rationale for treating a 71-year-old woman with ovarian cancer with the PARP inhibitor rucaparib upon relapse.